In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
about
Immunotherapy as treatment for Alzheimer’s diseaseUltrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse modelsA carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brainRobust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapyPharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid β protein antibody-coated nanoparticles.CNS delivery via adsorptive transcytosis.Agile delivery of protein therapeutics to CNSHuman intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's diseaseAutomated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI.In Vivo Amyloid-β Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody.Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-β in TgCRND8 mice.Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy.Combating immunosuppression in gliomaImmunization in Alzheimer's disease: naïve hope or realistic clinical potential?Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery.Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain.Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.Moving from the Dish to the Clinical Practice: A Decade of Lessons and Perspectives from the Pre-Clinical and Clinical Stem Cell Studies for Alzheimer's Disease.Recombinant Antibody Fragments for Neurodegenerative Diseases.Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Nanobiomaterials' applications in neurodegenerative diseases.N-terminal engineering of amyloid-β-binding Affibody molecules yields improved chemical synthesis and higher binding affinity.Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein.Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging.Antibody blood-brain barrier efflux is modulated by glycan modification.Unique molecular signatures of Alzheimer's disease amyloid β peptide mutations and deletion during aggregate/oligomer/fibril formation.Metal complexes for multimodal imaging of misfolded protein-related diseases.Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane.
P2860
Q22241491-FAAEE0B5-3D64-45C9-BC33-06C9EC3C5921Q27301343-8F10F55F-849C-47E3-B92D-D109C821DE5DQ27311201-7AC9C34C-797E-4852-9400-F5C0BFD745C8Q30499456-310F3C24-3CC4-4C03-8EE5-3B1E3C150C6AQ33805709-2B1E1A0E-E905-40A3-8404-9111B9339BDFQ33944437-7A156DC8-70CA-41D9-A528-135FD7226300Q33961318-F640F73B-03D9-46CD-8952-3F8937043770Q34013526-35911493-E708-445C-B5AA-AA1CB0878AE1Q34079647-3B5F4EDF-B7DC-447E-8375-BEC4681E6E5DQ34419295-DAA1EC13-A1C4-4A1F-B104-71258555BA39Q34538462-46EF8662-E82E-4A60-BF43-785A9270E38BQ36748573-B465E10B-439E-4AEF-B48B-F7AB40BFB28FQ36776410-E305B39C-B69B-4CCB-90D1-929509734E94Q37068847-1F87FB66-626A-41AC-A877-9C91A61BA16AQ37154213-80A5CB63-38E3-4866-A76E-A74580DB175AQ37179415-5D5CDE66-9D34-4F43-92FE-A315412C4AA8Q37310816-C6F5C77F-CC82-4C61-B9B0-877333685B1DQ37381344-6BF79EAA-3CFB-4EAA-9563-7F12CE73D708Q37674005-C7F1BD6E-6DF2-4ADC-8F45-68EB8D2B7E83Q38130176-1738064B-7401-4B6D-BF5B-997D4A3D0D99Q38843840-25DBC711-835F-4CDA-BCB8-9727B1AE9582Q38970823-5A38F688-7B37-47DD-97D3-587214066359Q39062945-A9D89866-DCE3-4803-A88C-2E2BBD91576EQ39126802-50BE4B72-E408-44F9-8186-72E0652E29A8Q39831866-31508A8F-5CAA-4520-A096-CEF45FB9671CQ42140359-677C7056-F6ED-4B81-8398-0B89C164B262Q42325913-CD8151FC-67BC-427E-AB60-7C17C487E8EFQ42590594-0E82FB08-1C2F-4F6D-95F6-59E284A6D5F2Q46348633-3DCEC62B-06C3-487F-BF08-CF71A7B3CFDDQ46817150-30A7FE6C-8C39-45F9-8E2D-7DFADDBBA70FQ47737459-0F42F32B-F417-42E0-BD5B-238D86B3E225Q52686864-7D27786F-6072-4F85-88F6-CD8F64DAE843
P2860
In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
In vivo targeting of antibody ...... ar imaging of amyloid plaques.
@en
type
label
In vivo targeting of antibody ...... ar imaging of amyloid plaques.
@en
prefLabel
In vivo targeting of antibody ...... ar imaging of amyloid plaques.
@en
P2093
P2860
P1476
In vivo targeting of antibody ...... ar imaging of amyloid plaques.
@en
P2093
Emily J Gilles
Geoffry L Curran
Joseph F Poduslo
Karunya K Kandimalla
Marina Ramirez-Alvarado
Muthu Ramakrishnan
Silvina S Holasek
Thomas M Wengenack
P2860
P304
P356
10.1111/J.1471-4159.2007.04591.X
P407
P577
2007-07-01T00:00:00Z